N-acetylaspartate synthase deficiency corrects the myelin phenotype in a canavan disease mouse model but does not affect survival time

Journal of Neuroscience

Volumn 35, Issue 43, 2015, Pages 14501-14516

  Maier, Helena ^a   Wang Eckhardt, Lihua ^a   Hartmann, Dieter ^a   Gieselmann, Volkmar ^a,b   Eckhardt, Matthias ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b Center for Rare Diseases   (Germany)

Author keywords

Aspartoacylase; Canavan disease; Leukodystrophy; N acetylaspartate; NAA synthase; Spongy degeneration

Indexed keywords

MYELIN; N ACETYLASPARTIC ACID; ACYLTRANSFERASE; AMIDASE; ASPARTIC ACID; ASPARTOACYLASE; ENZYME INHIBITOR; N-ACETYLASPARTATE; SPHINGOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANAVAN DISEASE; CONTROLLED STUDY; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; SURVIVAL; TRANSMISSION ELECTRON MICROSCOPY; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; FEMALE; GENETICS; GENOTYPE; GLIOSIS; KNOCKOUT MOUSE; MALE; METABOLISM; MYELIN SHEATH; NERVE DEGENERATION; NERVE FIBER; PATHOLOGY;

ACETYLTRANSFERASES; AMIDOHYDROLASES; ANIMALS; ASPARTIC ACID; AXONS; BEHAVIOR, ANIMAL; CANAVAN DISEASE; ENZYME INHIBITORS; FEMALE; GENOTYPE; GLIOSIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELIN SHEATH; NERVE DEGENERATION; SPHINGOLIPIDS; SURVIVAL ANALYSIS;

EID: 84945545744     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1056-15.2015     Document Type: Article

References (38)

1. Ahmed SS, Li H, Cao C, Sikoglu EM, Denninger AR, Su Q, Eaton S, Liso Navarro AA, Xie J, Szucs S, Zhang H, Moore C, Kirschner DA, Seyfried TN, Flotte TR, Matalon R, Gao G (2013) A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice. Mol Ther 21:2136–2147.
2. Arun P, Madhavarao CN, Moffett JR, Hamilton K, Grunberg NE, Ariyannur PS, Gahl WA, Anikster Y, Mog S, Hallows WC, Denu JM, Namboodiri AM (2010) Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease. J Inherit Metab Dis 33:195–210.
3. Baslow MH (2003) N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res 28:941–953.
4. Baslow MH, Guilfoyle DN (2013) Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions. Biochimie 95:946–956.
5. Becker I, Wang-Eckhardt L, Yaghootfam A, Gieselmann V, Eckhardt M (2008) Differential expression of (dihydro)ceramide synthases in mouse brain: oligodendrocyte-specific expression of CerS2/Lass2. Histochem Cell Biol 129:233–241.
6. Becker I, Lodder J, Gieselmann V, Eckhardt M (2010) Molecular characterization of N-acetylaspartylglutamate synthetase. J Biol Chem 285:29156–29164.
7. Bjartmar C, Battistuta J, Terada N, Dupree E, Trapp BD (2002) N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 51:51–58.
8. Burlina AP, Corazza A, Ferrari V, Erhard P, Künnecke B, Seelig J, Burlina AB (1994) Detection of increased urinary N-acetylaspartylglutamate in Canavan disease. Eur J Pediatr 153:538–539.
9. Canavan MM (1931) Schilder’s encephalitis periaxialis diffusa: Report of a case in a child aged sixteen and one-half months. Archives of Neurology& Psychiatry 25:299–308.
10. Chakraborty G, Mekala P, Yahya D, Wu G, Ledeen RW (2001) Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem 78:736–745.
11. Collard F, Stroobant V, Lamosa P, Kapanda CN, Lambert DM, Muccioli GG, Poupaert JH, Opperdoes F, Van Schaftingen E (2010) Molecular identification of N-acetylaspartylglutamate synthase and beta-citrylglutamate synthase. J Biol Chem 285:29826–29833.
12. D’Adamo AF Jr, Yatsu FM (1966) Acetate metabolism in the nervous system: N-acetyl-L-aspartic acid and the biosynthesis of brain lipids. J Neurochem 13:961–965.
13. Edwards K, Griffiths D, Morgan J, Pitman R, von Ruhland C (2009) Can the choice of intermediate solvent or resin affect glomerular basement membrane thickness? Nephrol Dial Transplant 24:400–403.
14. Guo F, Bannerman P, Mills Ko E, Miers L, Xu J, Burns T, Li S, Freeman E, McDonough JA, Pleasure D (2015) Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model. Ann Neurol 77:884–888.
15. Hogan B, Beddington R, Constantini F, Lacy E (1994) Manipulating the mouse embryo: a laboratory manual, Ed 2. New York: Cold Spring Harbor Laboratory.
16. Hoshino H, Kubota M (2014) Canavan disease: clinical features and recent advances in research. Pediatr Int 56:477–483.
17. Klugmann M, Leichtlein CB, Symes CW, Serikawa T, Young D, During MJ (2005) Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Mol Ther 11:745–753.
18. Ledeen RW, Wang J, Wu G, Lu ZH, Chakraborty G, Meyenhofer M, Tyring SK, Matalon R (2006) Physiological role of N-acetylaspartate: contribution to myelinogenesis. Adv Exp Med Biol 576:131–143; discussion 361–363.
19. Lodder-Gadaczek J, Becker I, Gieselmann V, Wang-Eckhardt L, Eckhardt M (2011) N-acetylaspartylglutamate synthetase II synthesizes N-acetylaspartylglutamylglutamate. J Biol Chem 286:16693–16706.
20. Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, Matalon R, Garbern J, Hristova D, Johnson A, Jiang W, Namboodiri MA (2005) Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan’s disease. Proc Natl Acad Sci U S A 102:5221–5226.
21. Magin TM, McWhir J, Melton DW (1992) A new mouse embryonic stem cell line with good germ line contribution and gene targeting frequency. Nucleic Acids Res 20:3795–3796.
22. Martin E, Capone A, Schneider J, Hennig J, Thiel T (2001) Absence of N-acetylaspartate in the human brain: impact on neurospectroscopy? Ann Neurol 49:518–521.
23. Matalon R, Michals K, Sebesta D, Deanching M, Gashkoff P, Casanova J (1988) Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 29:463–471.
24. Matalon R, Rady PL, Platt KA, Skinner HB, Quast MJ, Campbell GA, Matalon K, Ceci JD, Tyring SK, Nehls M, Surendran S, Wei J, Ezell EL, Szucs S (2000) Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med 2:165–175.
25. Matalon R, Michals-Matalon K, Surendran S, Tyring SK (2006) Canavan disease: studies on the knockout mouse. Adv Exp Med Biol 576:77–93; discussion 361–363.
26. Mersmann N, Tkachev D, Jelinek R, Röth PT, Möbius W, Ruhwedel T, Rühle S, Weber-Fahr W, Sartorius A, Klugmann M (2011) AspartoacylaselacZ knockin mice: an engineered model of Canavan disease. PLoS One 6:e20336.
27. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81:89–131.
28. Moffett JR, Arun P, Ariyannur PS, Garbern JY, Jacobowitz DM, Namboodiri AM (2011) Extensive aspartoacylase expression in the rat central nervous system. Glia 59:1414–1434.
29. Namboodiri AM, Moffett JR, Arun P, Mathew R, Namboodiri S, Potti A, Hershfield J, Kirmani B, Jacobowitz DM, Madhavarao CN (2006) Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease. Adv Exp Med Biol 576:145–163.
30. Pessentheiner AR, Pelzmann HJ, Walenta E, Schweiger M, Groschner LN, Graier WF, Kolb D, Uno K, Miyazaki T, Nitta A, Rieder D, Prokesch A, Bogner-Strauss JG (2013) NAT8L (N-acetyltransferase 8-like) accelerates lipid turnover and increases energy expenditure in brown adipocytes. J Biol Chem 288:36040–36051.
31. Surendran S, Ezell EL, Quast MJ, Wei J, Tyring SK, Michals-Matalon K, Matalon R (2004) Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain. Brain Res 1016:268–271.
32. Surendran S, Campbell GA, Tyring SK, Matalon R (2005) Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse. Neurobiol Dis 18:385–389.
33. Traka M, Wollmann RL, Cerda SR, Dugas J, Barres BA, Popko B (2008) Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. J Neurosci 28:11537–11549.
34. Truckenmiller ME, Namboodiri MA, Brownstein MJ, Neale JH (1985) N-Acetylation of L-aspartate in the nervous system: differential distribution of a specific enzyme. J Neurochem 45:1658–1662.
35. Wang J, Leone P, Wu G, Francis JS, Li H, Jain MR, Serikawa T, Ledeen RW (2009) Myelin lipid abnormalities in the aspartoacylase-deficient tremor rat. Neurochem Res 34:138–148.
36. Wiame E, Tyteca D, Pierrot N, Collard F, Amyere M, Noel G, Desmedt J, Nassogne MC, Vikkula M, Octave JN, Vincent MF, Courtoy PJ, Boltshauser E, van Schaftingen E (2009) Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartia. Biochem J 425:127–136.
37. Yaghootfam A, Gieselmann V, Eckhardt M (2005) Delay of myelin formation in arylsulphatase A-deficient mice. Eur J Neurosci 21:711–720.
38. Zöller I, Meixner M, Hartmann D, Büssow H, Meyer R, Gieselmann V, Eckhardt M (2008) Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. J Neurosci 28:9741–9754.